Clinical

Dataset Information

0

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

ABSTRACT: This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.

DISEASE(S): Other Metastatic Solid Tumors,Nsclc,Colorectal Cancer,Non-small Cell Lung Cancer,Advanced Solid Tumor,Esophageal Cancer,Head And Neck Cancer

PROVIDER: 2272421 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
| 2275986 | ecrin-mdr-crc
Clinical JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
| 2386408 | ecrin-mdr-crc
Clinical JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
| 2401233 | ecrin-mdr-crc
Clinical Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
| 2710011 | ecrin-mdr-crc
Clinical A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
| 2312891 | ecrin-mdr-crc
Genomics Shewanella bicestrii strain:JAB-1
| PRJNA393250 | ENA
Genomics Synechococcus sp. PEB' JAB'6FA
| PRJNA332360 | ENA
Genomics Synechococcus sp. PEB' JAB'6FD
| PRJNA332361 | ENA
Clinical A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
| 2318715 | ecrin-mdr-crc
Clinical MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
| 2194587 | ecrin-mdr-crc